CRISPR-Cas9 Fusion Proteins Modulate Alpha-Synuclein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease are entirely symptomatic and do not address the underlying disease progression, representing a significant unmet medical need for innovative neuromodulatory therapeutic approaches.
Innovation Solution
Development of recombinant DNA molecules encoding fusion proteins comprising a CRISPR-associated nuclease, such as Cas9, and a transcriptional repressor, which can be used to modulate alpha-synuclein expression by targeting specific sequences in the alpha-synuclein gene or its regulatory regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments are used for Parkinson's disease, then symptom management is achieved, but disease progression cannot be halted or slowed
Solution Approach 1:
The patent extracts and targets the specific alpha-synuclein gene (SNCA) as the root cause of disease progression, separating the therapeutic action from general symptomatic treatment. By using CRISPR-Cas9 to specifically modulate SNCA expression, the invention removes the underlying pathological driver rather than merely managing symptoms.
Solution Approach 2:
The patent employs preliminary action by modulating alpha-synuclein expression before disease progression occurs. The CRISPR-Cas9 system is designed to pre-regulate gene expression, preventing the formation of toxic aggregates and neuronal damage before they manifest as clinical symptoms, thereby halting progression rather than treating existing damage.
2Reliability
If CRISPR-Cas9 system is used to modulate alpha-synuclein expression, then disease progression can be slowed or halted, but off-target effects and safety concerns arise
Solution Approach 1:
The patent applies local quality by designing CRISPR-Cas9 components with high specificity for the alpha-synuclein gene locus. The guide RNA sequences are carefully selected to target only the SNCA gene, and the system is deployed in a localized manner (e.g., intrathecal injection to target brain regions) to minimize off-target effects while maximizing therapeutic impact on the specific disease-causing gene.
Solution Approach 2:
The patent uses an intermediary approach by employing a modified CRISPR-Cas9 system with reduced catalytic activity or enhanced regulation. The system includes control mechanisms such as titratable promoters, inducible expression, or engineered Cas9 variants that provide graded activity, allowing precise control over gene modulation while minimizing harmful off-target effects.
3Reliability
If alpha-synuclein expression is modulated, then protein aggregation and neurodegeneration are reduced, but gene editing complexity and delivery challenges increase
Solution Approach 1:
The patent applies segmentation by dividing the gene editing system into separate functional components: guide RNA molecules, CRISPR-Cas9 enzyme complex, and delivery vector. This modular approach allows independent optimization of each component and simplifies the delivery process, as each segment can be tailored to specific requirements for brain penetration and gene targeting.
Solution Approach 2:
The patent replaces complex mechanical gene editing systems with a more manageable molecular approach. Instead of using complex viral vectors or physical delivery methods, the invention employs simplified CRISPR-Cas9 complexes that can be delivered through established routes (e.g., intrathecal injection), reducing the mechanical complexity of the delivery system while maintaining editing efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively decreases alpha-synuclein protein expression, potentially slowing or halting disease progression in Parkinson's disease, as demonstrated by significant downregulation of alpha-synuclein mRNA and protein levels in various brain regions.
Implementation Method 1
recombinant DNA molecules encoding fusion proteins comprising a CRISPR-associated nuclease, such as Cas9, and a transcriptional repressor, which can be used to modulate alpha-synuclein expression by targeting specific sequences in the alpha-synuclein gene or its regulatory regions
Implementation Method 2
fusion proteins comprising a CRISPR-associated nuclease, such as Cas9, and a transcriptional repressor, which can be used to modulate alpha-synuclein expression
Data Source
AI summary
This disclosure provides recombinant DNA mol-encoding fusion proteins that are able to regulate expression of alpha-synuclein. Also provided are various compositions comprising the recombinant DNA molecules, as well as associated methods of use. The recombinant DNA molecules and associated methods are useful for the treatment of subjects having disorders caused by excess expression or intracellular accumulation of alpha-synuclein, including Parkinson's disease.